Results 201 to 210 of about 15,566 (231)

Polymorphism analysis of CYP3A5 in myeloid leukemia

Oncology Reports, 2002
The human cytochrome P450 (CYP) metabolizes more than 100 structurally diverse exogenous and endogenous molecules. The CYP3A5 is a major P450 enzyme in the liver and represents 50% of the total hepatic CYP3A content in people expressing CYP3A5. The single nucleotide polymorphisms in CYP3A5*3 and CYP3A5*6 that resulted in the absence of CYP3A5 from ...
Ta-Chih, Liu, Sheng-Fung, Lin, Tyen-Po, Chen, Jan-Gowth, Chang   +3 more
openaire   +2 more sources

Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations

Pharmacogenetics and Genomics, 2011
We investigated the pharmacokinetic and pharmacogenetic implications of conversion from a twice-daily (P-Tac) to a once-daily (A-Tac) tacrolimus (Tac) formulation.We analyzed Tac levels in a cohort of 41 renal transplant patients with a stable graft function over a period of 1 year before and after conversion.After conversion, the patients had, on ...
Markus, Wehland, Steffen, Bauer, Susanne, Brakemeier, Philip, Burgwinkel, Petra, Glander, Reinhold, Kreutz, Christine, Lorkowski, Torsten, Slowinski, Hans H, Neumayer, Klemens, Budde   +9 more
openaire   +2 more sources

Expression and Localization of CYP3A4 and CYP3A5 in Human Lung

American Journal of Respiratory Cell and Molecular Biology, 1997
Abstract Expression in the lung of procarcinogen-metabolizing P450 enzymes in the CYP3A subfamily may contribute to the initiation of pulmonary carcinogenesis by agents that require metabolic activation, such as tobacco-derived polycyclic aromatic hydrocarbons.
S, Anttila, J, Hukkanen, J, Hakkola, T, Stjernvall, P, Beaune, R J, Edwards, A R, Boobis, O, Pelkonen, H, Raunio   +8 more
openaire   +2 more sources

Novel detection assay by PCR???RFLP and frequency of the CYP3A5 SNPs, CYP3A5 *3 and *6, in a Japanese population

Pharmacogenetics, 2002
In this study, we established useful and reliable methods for the direct detection of the variants of CYP3A5 gene by polymerase chain reaction (PCR) and DdeI restriction analysis. The frequency of CYP3A5 related SNPs in 200 healthy Japanese male subjects was determined. The homozygous wild-type (*1/*1) frequency was 7.0% (14/200), the heterozygous (*1/*
Shuichi, Fukuen, Tsuyoshi, Fukuda, Hiromi, Maune, Yuka, Ikenaga, Isamu, Yamamoto, Tadanobu, Inaba, Junichi, Azuma   +6 more
openaire   +2 more sources

The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism

Toxicology Letters, 2019
Cytochrome P450 mediated metabolism is the rate-limiting step of elimination for many drugs. CYP3A4 is the most abundant hepatic isoform and CYP3A4/5 metabolize the largest fraction of drugs. Pharmacogenetic studies have not been able to characterize population variability in CYP3A4 activity because few variant alleles associated with aberrant enzyme ...
Joseph McGraw, Mitchell Cherney, Katherine Bichler, Armin Gerhardt, Mirielle Nauman   +4 more
openaire   +2 more sources

CYP3A5 genotype is associated with elevated blood pressure

Pharmacogenetics and Genomics, 2005
The present study aimed to determine whether a polymorphism in CYP3A5, encoding the major CYP3A enzyme in the human kidney, is associated with blood pressure in Caucasians. A homogenous group of 115 young, white male students with normal or mildly elevated, but untreated blood pressure was included.
Martin F, Fromm, Bernhard M W, Schmidt, Andreas, Pahl, Johannes, Jacobi, Roland E, Schmieder   +4 more
openaire   +2 more sources

In vitro metabolism of cyclosporine A by human kidney CYP3A5

Biochemical Pharmacology, 2004
The objectives of this study were to characterize and compare the metabolic profile of cyclosporine A (CsA) catalyzed by CYP3A4, CYP3A5 and human kidney and liver microsomes, and to evaluate the impact of the CYP3A5 polymorphism on product formation from parent drug and its primary metabolites.
Yang, Dai, Kazunori, Iwanaga, Yvonne S, Lin, Mary F, Hebert, Connie L, Davis, Weili, Huang, Evan D, Kharasch, Kenneth E, Thummel   +7 more
openaire   +2 more sources

Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs

Current Drug Metabolism, 2016
The contribution of the CYP3A5 enzyme to the metabolism of clinically used drugs has been established only for a few CYP3A substrates, such as the immunosuppressant tacrolimus, while for drugs used in the field of psychiatry its role is still vague.We herein discuss all published data on the contribution of CYP3A5 and its polymorphisms to the ...
Georgia, Ragia, Marja-Liisa, Dahl, Vangelis G, Manolopoulos   +2 more
openaire   +2 more sources

ผลของยาดิลไทอะเซ็มและภาวะพหุสัณฐานของยีน CYP3A5 ต่อระดับความเข้มข้นของยาทาโครลิมุสในผู้ป่วยปลูกถ่ายไตชาวไทย

2018
วัตถุประสงค์: เพื่อเปรียบเทียบค่าเฉลี่ยของระดับความเข้มข้นต่ำ สุดของยา tacrolimus ในเลือดต่อขนาดยาและเปรียบเทียบสัดส่วนของจำนวนผู้ป่วยปลูกถ่ายไตในสภาวะคงที่ที่มีระดับความเข้มต่ำสุดของ tacrolimus อยู่ในเป้าหมาย 6-8 นาโนกรัมต่อมิลลิลิตร ในเดือนที่ 6 ภายหลังการปลูกถ่ายไต ในผู้ป่วยปลูกถ่ายไตชาวไทยที่ได้รับและไม่ได้รับยา diltiazem ขนาด 240 มิลลิกรัมต่อวัน ผู
openaire   +1 more source

Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7

Drug Metabolism and Disposition, 2002
The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50% of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5 contributes more significantly to the total liver CYP3A than was originally thought. CYP3A7 is the major fetal form and is rarely expressed in adults.
J Andrew, Williams, Barbara J, Ring, Varon E, Cantrell, David R, Jones, James, Eckstein, Kenneth, Ruterbories, Mitchell A, Hamman, Stephen D, Hall, Steven A, Wrighton   +8 more
openaire   +2 more sources